0000950170-24-084346.txt : 20240717
0000950170-24-084346.hdr.sgml : 20240717
20240717173534
ACCESSION NUMBER: 0000950170-24-084346
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240715
FILED AS OF DATE: 20240717
DATE AS OF CHANGE: 20240717
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Knight Jeff E.
CENTRAL INDEX KEY: 0001881007
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38583
FILM NUMBER: 241123128
MAIL ADDRESS:
STREET 1: CRINETICS PHARMACEUTICALS, INC.
STREET 2: 10222 BARNES CANYON ROAD, BUILDING 2
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Crinetics Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001658247
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 263744114
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10222 BARNES CANYON ROAD, BLDG. #2
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-450-6464
MAIL ADDRESS:
STREET 1: 10222 BARNES CANYON ROAD, BLDG. #2
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
ownership.xml
4
X0508
4
2024-07-15
false
0001658247
Crinetics Pharmaceuticals, Inc.
CRNX
0001881007
Knight Jeff E.
C/O CRINETICS PHARMACEUTICALS, INC.
6055 LUSK BOULEVARD
SAN DIEGO
CA
92121
false
true
false
false
Chief Operating Officer
true
Common Stock
2024-07-15
4
M
false
17499
23.98
A
70079
D
Common Stock
2024-07-15
4
M
false
2887
20.02
A
72966
D
Common Stock
2024-07-15
4
M
false
5687
19.64
A
78653
D
Common Stock
2024-07-15
4
S
false
27000
55.00
D
51653
D
Stock option (Right to Buy)
23.98
2024-07-15
4
M
false
17499
0
D
2031-09-01
Common Stock
17499
112501
D
Stock option (Right to Buy)
20.02
2024-07-15
4
M
false
2887
0
D
2032-02-29
Common Stock
2887
20213
D
Stock option (Right to Buy)
19.64
2024-07-15
4
M
false
5687
0
D
2033-03-01
Common Stock
5687
85313
D
The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The option is exercisable as follows: 25% of the shares subject to the option vest on August 30, 2022, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.
1/48th of the shares subject to the option vested on March 31, 2022, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.
1/48th of the shares subject to the option vested on April 1, 2023, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.
Marc Wilson, as attorney-in-fact
2024-07-17